Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1991;17:107-115

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rhaleb, N. E.
Right arrow Articles by Regoli, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rhaleb, N. E.
Right arrow Articles by Regoli, D.

Hypertension, Vol 17, 107-115, Copyright © 1991 by American Heart Association


ARTICLES

Structure-activity studies of bradykinin and related peptides. B2- receptor antagonists

NE Rhaleb, S Telemaque, N Rouissi, S Dion, D Jukic, G Drapeau and D Regoli
Medical School, University of Sherbrooke, Quebec, Canada.

Thirty-seven compounds were tested as antagonists of kinin B2- and B1- receptors to identify the chemical changes required to obtain antagonism, improve antagonist affinity, and eliminate residual agonistic activities. Apparent affinity of antagonists was evaluated in terms of pA2 on the rabbit jugular vein, the dog carotid and renal arteries, the hamster urinary bladder, the guinea pig ileum, the rat vas deferens, the guinea pig trachea, and the rabbit aorta, using bradykinin and desArg9-bradykinin as B2- and B1-receptor activators. Replacement of Pro7 of bradykinin with D-Phe leads to antagonism; substitution of Pro3 by Hyp and extension of the peptide chain at the N- terminal with a D-Arg residue improves the affinity of antagonists; acetylation of N-terminal amine function reduces residual agonistic activity; these changes, combined with the replacement of Phe8 by Leu as in Ac-D-Arg[Hyp3,D-Phe7,Leu8]-bradykinin, led to potent full B2- receptor antagonists. Affinity of antagonists differs markedly between highly sensitive (rabbit jugular vein, dog carotid and renal artery), moderately sensitive (hamster urinary bladder, guinea pig ileum, and rat vas deferens), and insensitive preparations (the guinea pig trachea) in which antagonists act as potent stimulants. High concentrations of antagonists block bradykinin completely in the rabbit jugular vein but not in the guinea pig ileum, suggesting that kinins stimulate the moderately sensitive tissues by two mechanisms, of which only one is blocked by antagonists. It thus appears that kinins act on various B2-receptor subtypes or by different action mechanisms.


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
T. C. Peterson, M. R. Peterson, H. A. Robertson, M. During, and M. Dragunow
Selective Down-Regulation of c-jun Gene Expression by Pentoxifylline and c-jun Antisense Interrupts Platelet-Derived Growth Factor Signaling: Pentoxifylline Inhibits Phosphorylation of c-Jun on Serine 73
Mol. Pharmacol., June 1, 2002; 61(6): 1476 - 1488.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. Houle, J.-F. Larrivee, M. Bachvarova, J. Bouthillier, D. R. Bachvarov, and F. Marceau
Antagonist-Induced Intracellular Sequestration of Rabbit Bradykinin B2 Receptor
Hypertension, June 1, 2000; 35(6): 1319 - 1325.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Emanueli, E. Fink, A. F. Milia, M. B. Salis, M. Conti, M. P. Demontis, and P. Madeddu
Enhanced Blood Pressure Sensitivity to Deoxycorticosterone in Mice With Disruption of Bradykinin B2 Receptor Gene
Hypertension, June 1, 1998; 31(6): 1278 - 1283.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Madeddu, M. V. Varoni, D. Palomba, C. Emanueli, M. P. Demontis, N. Glorioso, P. Dessi-Fulgheri, R. Sarzani, and V. Anania
Cardiovascular Phenotype of a Mouse Strain With Disruption of Bradykinin B2-Receptor Gene
Circulation, November 18, 1997; 96(10): 3570 - 3578.
[Abstract] [Full Text]


Home page
HypertensionHome page
F. Gobeil, W. Neugebauer, C. Filteau, D. Jukic, S. N. Allogho, L. H. Pheng, X. K. Nguyen-Le, D. Blouin, and D. Regoli
Structure-Activity Studies of B1 Receptor–Related Peptides: Antagonists
Hypertension, November 1, 1996; 28(5): 833 - 839.
[Abstract] [Full Text]


Home page
HypertensionHome page
P. Madeddu, P. P. Parpaglia, M. P. Demontis, M. V. Varoni, M. C. Fattaccio, V. Anania, and N. Glorioso
Early Blockade of Bradykinin B2-Receptors Alters the Adult Cardiovascular Phenotype in Rats
Hypertension, March 1, 1995; 25(3): 453 - 459.
[Abstract] [Full Text]